Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

"The drop in shares comes as market sees near-term concerns over the company's muted U.S. sales," said Sumit Gupta, analyst at Centrum Broking. Indian generic drugmakers are struggling with slower ...

A U.S. Federal Claims Court judge shot down Vanda Pharmaceuticals Inc.’s accusations that the FDA disclosed the company’s trade secrets to generic competitors, finding that the trade secrets weren’t ...

The FDA dodged claims from Van­da Phar­ma­ceu­ti­cals that it al­leged­ly vi­o­lat­ed the US Con­sti­tu­tion by rec­om­mend­ing the same drug spec­i­fi­ca­tions for both Van ...

NASDAQ:VNDA opened at $4.36 on Monday. The company has a market cap of $254.23 million, a P/E ratio of -15.57 and a beta of 0.77. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Subscribe to our FREE Newsletter, or Telegram and WhatsApp channels for the latest stories and updates. Malaysia’s first glass water slide is ready to welcome visitors at i-City Shah Alam as part of ...

Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.